<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01754714</url>
  </required_header>
  <id_info>
    <org_study_id>M13-397</org_study_id>
    <secondary_id>2012-000975-18</secondary_id>
    <nct_id>NCT01754714</nct_id>
  </id_info>
  <brief_title>Study to Investigate the Effects of Different Doses of S-adenosyl-L-methionine (SAMe) in Subjects With Nonalcoholic Fatty Liver Disease and Non-treated Matched Healthy Volunteers as Control Group</brief_title>
  <acronym>EXPO</acronym>
  <official_title>Open-label, Randomized, Parallel-Group, Exploratory Study to Investigate the Effects of Different Doses of S-adenosyl-L-methionine (SAMe) in Subjects With Nonalcoholic Steatohepatitis (NASH) and Non-treated Matched Healthy Volunteers as Control Group</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PPD</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Abbott</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigation the Effects of Different Doses of SAMe in Subjects with Nonalcoholic Fatty
      Liver Disease and non-treated matched healthy volunteers as control group
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Methionine Elimination Half-life Measured in Blood.</measure>
    <time_frame>0.5, 1, 1.5, 3, 4.5, 6, 7.5 and 9 hours*at Week 7*</time_frame>
    <description>After the methionine load, blood samples will be obtained at 0.5, 1, 1.5, 3, 4.5, 6, 7.5 and 9 hours. Plasma will be analyzed for methionine.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fasting Methionine Concentration of Average Methionine Concentration Versus Time Curve.</measure>
    <time_frame>0.5, 1, 1.5, 3, 4.5, 6, 7.5 and 9 hours*at Week 7*</time_frame>
    <description>After the methionine load, blood samples will be obtained at 0.5, 1, 1.5, 3, 4.5, 6, 7.5 and 9 hours. Plasma will be analyzed for methionine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>13 Carbon (Natural, Stable Isotope of Carbon) Methionine Breath Test</measure>
    <time_frame>0.5, 1, 1.5, 3, 4.5, 6, 7.5 and 9 hours*at Week 7*</time_frame>
    <description>parameters cumulative percentage dose of 13 carbon recovered after 30, 60, 90 minutes (cPDR30, cPDR60, cPDR 90) will be evaluated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatic Panel (Liver Laboratory Parameters)</measure>
    <time_frame>change from baseline at 6 weeks</time_frame>
    <description>Serum Total Bilirubin (STB), Serum Conjugated Bilirubin (SCB), liver-alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), Gamma Glutamyl Transpeptidase (GGT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic Panel (Metabolic Laboratory Parameters)</measure>
    <time_frame>change from baseline at 6 weeks</time_frame>
    <description>Fasting lipid profile (cholesterol, HDL (High Density Lipoprotein), LDL (Low Density Lipoprotein)), amino acid profile, homeostasis model assessment (HOMA-R) and fasting glucose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Metabolic Clearance Rate Measured in the Blood.</measure>
    <time_frame>0.5, 1, 1.5, 3, 4.5, 6, 7.5 and 9 hours*at Week 7*</time_frame>
    <description>After the methionine load, blood samples will be obtained at 0.5, 1, 1.5, 3, 4.5, 6, 7.5 and 9 hours. Plasma will be analyzed for methionine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Methionine Volume of Distribution at Week 7 (L)</measure>
    <time_frame>0.5, 1, 1.5, 3, 4.5, 6, 7.5 and 9 hours*at Week 7*</time_frame>
    <description>After the methionine load, blood samples will be obtained at 0.5, 1, 1.5, 3, 4, 5, 6, 7.5 and 9 hours. Plasma will be analyzed for methionine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>13 Carbon (Natural, Stable Isotope of Carbon) Methionine Breath Test</measure>
    <time_frame>0.5, 1, 1.5, 3, 4.5, 6, 7.5 and 9 hours*at Week 7*</time_frame>
    <description>Peak</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>13 Carbon (Natural, Stable Isotope of Carbon) Methionine Breath Test</measure>
    <time_frame>0.5, 1, 1.5, 3, 4.5, 6, 7.5 and 9 hours*at Week 7*</time_frame>
    <description>Time to peak</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic Panel (Metabolic Laboratory Parameters)</measure>
    <time_frame>Change from baseline at 6 weeks</time_frame>
    <description>Fasting plasma insulin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic Panel (Metabolic Laboratory Parameters)</measure>
    <time_frame>change from baseline at 6 weeks</time_frame>
    <description>glycosylated hemoglobin (HbA1c)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic Panel (Metabolic Laboratory Parameters)</measure>
    <time_frame>change from baseline at 6 weeks</time_frame>
    <description>Adiponectin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunological/Anti-oxidant Panel (Immunological and Anti-oxidant Laboratory Parameters)</measure>
    <time_frame>change from baseline at 6 weeks</time_frame>
    <description>C-reactive Protein (CRP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunological/Anti-oxidant Panel (Immunological and Anti-oxidant Laboratory Parameters)</measure>
    <time_frame>change from baseline at 6 weeks</time_frame>
    <description>glutathione in erythrocytes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunological/Anti-oxidant Panel (Immunological and Anti-oxidant Laboratory Parameters)</measure>
    <time_frame>change from baseline at 6 weeks</time_frame>
    <description>oxidative stress marker (isoprostane level)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrosis and Apoptosis Markers (Fibrosis and Apoptosis Laboratory Markers)</measure>
    <time_frame>change from baseline at 6 weeks</time_frame>
    <description>Caspase-cleaved cytokeratin (CK 18)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrosis and Apoptosis Markers (Fibrosis and Apoptosis Laboratory Markers)</measure>
    <time_frame>change from baseline at 6 weeks</time_frame>
    <description>Hyaluronic acid</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under Curve (AUC) of Average Methionine Concentration Versus Time Curve</measure>
    <time_frame>0.5, 1, 1.5, 3, 4, 5, 6, 7.5 and 9 hours *at Week 7*</time_frame>
    <description>After the methionine load, blood samples will be obtained at 0.5, 1, 1.5, 3, 4, 5, 6, 7.5 and 9 hours. Plasma will be analyzed for methionine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatic Panel (Liver Laboratory Parameters)</measure>
    <time_frame>change from baseline at 6 weeks</time_frame>
    <description>ALT/AST ratio</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Immunological/Anti-oxidant Panel (Immunological and Anti-oxidant Laboratory Parameters)</measure>
    <time_frame>change from baseline at 6 weeks</time_frame>
    <description>Cytokine profile ( Interleukin-6, IL-8, IL-10 (IL), Tumor Necrosis Factor (TNF -α), monocyte chemoattractant protein (MCP-1), and Granulocyte-colony stimulating factor (G-CSF ).</description>
  </other_outcome>
  <other_outcome>
    <measure>Fibrosis and Apoptosis Markers (Fibrosis and Apoptosis Laboratory Markers)</measure>
    <time_frame>change from baseline at 6 weeks</time_frame>
    <description>Non-invasive test for liver disease (ActiTest)/Fibrotest
FibroTest® : diagnoses hepatic fibrosis ActiTest® : assesses viral necro-inflammatory activity Scores between 0 and 1, the higher the score the worse
The FibroTest score is calculated from the results of a six-parameter blood test, combining six serum markers with the age and gender of the patient:Alpha-2-macroglobulin, Haptoglobin, Apolipoprotein A1, Gamma-glutamyl transpeptidase (GGT), Total bilirubin, and Alanine transaminase (ALT). ALT is used in a second assessment called ActiTest that is part of FibroTest.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">108</enrollment>
  <condition>Non Alcoholic Fatty Liver Disease</condition>
  <arm_group>
    <arm_group_label>1000 mg SAMe (S-adenosyl-L-methionine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>1500 mg SAMe</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2000 mg SAMe</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>No treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SAMe 1000 mg</intervention_name>
    <description>1000 mg dose group: one 500 mg capsule fasting in the morning and one 500 mg capsule before dinner</description>
    <arm_group_label>1000 mg SAMe (S-adenosyl-L-methionine)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SAMe 1500 mg</intervention_name>
    <description>1500 mg dose group: two 500 mg capsules fasting in the morning and one 500 mg capsule before dinner</description>
    <arm_group_label>1500 mg SAMe</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SAMe 2000 mg</intervention_name>
    <description>2000 mg dose group: two 500 mg capsules fasting in the morning and two 500 mg capsules before dinner</description>
    <arm_group_label>2000 mg SAMe</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Subjects with non-alcoholic steatohepatitis based on histology in medical history
             within the last 3 years

          -  Subjects in a stable metabolic condition since histology for NASH (Non-alcoholic
             Steatohepatitis)

        Exclusion Criteria

          -  Subjects with extrahepatic biliary obstruction

          -  Subjects with primary sclerosing cholangitis (PSC)

          -  Subjects with primary biliary cirrhosis (PBC)

          -  Any form of malignancy within the past 5 years and/or basal cell carcinoma and
             squamous cell carcinoma of the skin within the past two years

          -  History of active substance abuse (oral, inhaled or injected) within one year prior to
             the study

          -  Subjects with renal impairment (creatinine level of &gt;2.0 mg/dL)

          -  Subjects with a known hypersensitivity to the active substance (ademetionine) or
             methionine or to any of the inactive ingredients

          -  Subjects with known genetic defects affecting the methionine cycle and/or causing
             homocystinuria and/or hyperhomocysteinemia (e.g., cystathionine beta-synthase
             deficiency, Vitamin B12 metabolism defect)

          -  Subjects on total parenteral nutrition in the year prior to screening

          -  Subjects after or planned for bariatric surgery (jejunoileal bypass or gastric weight
             loss surgery)

          -  Extrahepatic cholestasis (proven by ultrasound)

          -  Subjects with alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) &gt;
             5 upper limit of normal (ULN)

          -  Subject with serum total bilirubin (STB) &gt; 5 ULN

          -  Subjects after liver transplantation and subjects on the waiting list for liver
             transplantation

          -  Subjects with any of the following disease in medical history:

          -  Viral hepatitis (serum positive HBcAb (hepatitis B core antibody) or Hepatitis C Virus
             (HCV) ribonucleic acid (RNA)

          -  Evidence of autoimmune liver disease

          -  Wilson's disease

          -  Hemochromatosis

          -  Alpha-1-antitrypsin deficiency

          -  Known positivity for antibody to human immunodeficiency virus (HIV)

          -  Known heart failure of New York heart Association class 3 or 4

          -  Current or history of significant alcohol consumption for a period of more than three
             consecutive months within five years prior to screening (significant alcohol
             consumption is defined as &gt; 3 U (unit)/day for men and &gt; 2 U/day for women, on
             average) or binge drinking or inability to reliably quantify alcohol consumption.

          -  Clinical or histological evidence of cirrhosis F4

          -  Subjects with history of biliary diversion

          -  Subjects with uncontrolled diabetes mellitus defined by HbA1c (hemoglobin A1c) &gt; 8.0 %
             at screening

          -  Concomitant medication of B12, folate, betaine or choline

          -  Concomitant treatment with glitazone within the past year prior to the study

          -  Subjects with known folate or B12 deficiency

          -  BMI (body mass index) &gt; 40 kg/m2

          -  History of major depression diagnostic and statistical manual of mental disorders
             (DSM-IV) or bipolar disease

          -  Women of childbearing potential: positive urine pregnancy test during screening or
             unwillingness to use an effective form of birth control during the study.

          -  Breastfeeding women

          -  Any condition that, in the opinion of the investigator, does not justify the patient's
             inclusion into the study

          -  Investigational drug intake within one month prior to the study

          -  Active, serious medical disease with likely life-expectancy less than five years

          -  Uncooperative attitude or reasonable likelihood for non-compliance with the protocol
             or any other reason that, in the investigator's opinion, prohibits the inclusion of
             the subject into the study

          -  Legal incapacity or limited legal capacity, or who are incarcerated.

          -  Inability to return for scheduled visits.

          -  Inability to understand and follow the requirements of the protocol in the local
             language
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suntje Sander-Struckmeier, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Abbott</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID 93914</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID 93895</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID 93894</name>
      <address>
        <city>Bobigny</city>
        <zip>93009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID 93913</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID 93916</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID 93915</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID 93893</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID 93896</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID 93953</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID 93954</name>
      <address>
        <city>Frankfurt</city>
        <zip>60594</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID 93935</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID 93955</name>
      <address>
        <city>Halle</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID 93917</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID 93933</name>
      <address>
        <city>Homburg</city>
        <zip>66424</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID 94015</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID 93918</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID 94014</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site reference ID/Investigator # 109455</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-030</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID 93958</name>
      <address>
        <city>Chorzow</city>
        <zip>41-500</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID 93973</name>
      <address>
        <city>Krakow</city>
        <zip>31-531</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID 93956</name>
      <address>
        <city>Lodz</city>
        <zip>91-347</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID 93957</name>
      <address>
        <city>Myslowice</city>
        <zip>41-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID 93974</name>
      <address>
        <city>Warsaw</city>
        <zip>02-507</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID 93975</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-220</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site reference ID ORG-000905</name>
      <address>
        <city>Krasnoyarsk</city>
        <zip>660022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site reference ID ORG-000906</name>
      <address>
        <city>Moscow</city>
        <zip>119435</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site reference ID ORG-000900</name>
      <address>
        <city>Nizhniy Novgorod</city>
        <zip>603126</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site reference ID ORG-000907</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630084</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site reference ID ORG-000903</name>
      <address>
        <city>Omsk</city>
        <zip>644043</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site reference ID ORG-000920</name>
      <address>
        <city>Rostov-on-Don</city>
        <zip>344022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site reference ID ORG-000904</name>
      <address>
        <city>Samara</city>
        <zip>443011</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site reference ID ORG-000901</name>
      <address>
        <city>Stavropol</city>
        <zip>355017</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Poland</country>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2012</study_first_submitted>
  <study_first_submitted_qc>December 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2012</study_first_posted>
  <results_first_submitted>October 2, 2015</results_first_submitted>
  <results_first_submitted_qc>January 22, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 19, 2016</results_first_posted>
  <last_update_submitted>January 22, 2016</last_update_submitted>
  <last_update_submitted_qc>January 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Steatohepatitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>1000 mg SAMe (S-adenosyl-L-methionine)</title>
          <description>SAMe 1000 mg: 1000 mg dose group: one 500 mg capsule fasting in the morning and one 500 mg capsule before dinner</description>
        </group>
        <group group_id="P2">
          <title>1500 mg SAMe</title>
          <description>SAMe 1500 mg: 1500 mg dose group: two 500 mg capsules fasting in the morning and one 500 mg capsule before dinner</description>
        </group>
        <group group_id="P3">
          <title>2000 mg SAMe</title>
          <description>SAMe 2000 mg: 2000 mg dose group: two 500 mg capsules fasting in the morning and two 500 mg capsules before dinner</description>
        </group>
        <group group_id="P4">
          <title>No Treatment</title>
          <description>No study drug was administered</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="27"/>
                <participants group_id="P3" count="26"/>
                <participants group_id="P4" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="24"/>
                <participants group_id="P4" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>1000 mg SAMe (S-adenosyl-L-methionine)</title>
          <description>SAMe 1000 mg: 1000 mg dose group: one 500 mg capsule fasting in the morning and one 500 mg capsule before dinner</description>
        </group>
        <group group_id="B2">
          <title>1500 mg SAMe</title>
          <description>SAMe 1500 mg: 1500 mg dose group: two 500 mg capsules fasting in the morning and one 500 mg capsule before dinner</description>
        </group>
        <group group_id="B3">
          <title>2000 mg SAMe</title>
          <description>SAMe 2000 mg: 2000 mg dose group: two 500 mg capsules fasting in the morning and two 500 mg capsules before dinner</description>
        </group>
        <group group_id="B4">
          <title>No Treatment</title>
          <description>no study drug was administered</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="27"/>
            <count group_id="B2" value="27"/>
            <count group_id="B3" value="26"/>
            <count group_id="B4" value="28"/>
            <count group_id="B5" value="108"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.2" spread="13.8"/>
                    <measurement group_id="B2" value="50.0" spread="12.3"/>
                    <measurement group_id="B3" value="49.5" spread="14.2"/>
                    <measurement group_id="B4" value="56.6" spread="11.6"/>
                    <measurement group_id="B5" value="51.9" spread="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Russian Federation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Methionine Elimination Half-life Measured in Blood.</title>
        <description>After the methionine load, blood samples will be obtained at 0.5, 1, 1.5, 3, 4.5, 6, 7.5 and 9 hours. Plasma will be analyzed for methionine.</description>
        <time_frame>0.5, 1, 1.5, 3, 4.5, 6, 7.5 and 9 hours*at Week 7*</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1000 mg SAMe (S-adenosyl-L-methionine)</title>
            <description>SAMe 1000 mg: 1000 mg dose group: one 500 mg capsule fasting in the morning and one 500 mg capsule before dinner</description>
          </group>
          <group group_id="O2">
            <title>1500 mg SAMe</title>
            <description>SAMe 1500 mg: 1500 mg dose group: two 500 mg capsules fasting in the morning and one 500 mg capsule before dinner</description>
          </group>
          <group group_id="O3">
            <title>2000 mg SAMe</title>
            <description>SAMe 2000 mg: 2000 mg dose group: two 500 mg capsules fasting in the morning and two 500 mg capsules before dinner</description>
          </group>
          <group group_id="O4">
            <title>No Treatment</title>
            <description>No study drug was administered</description>
          </group>
        </group_list>
        <measure>
          <title>Methionine Elimination Half-life Measured in Blood.</title>
          <description>After the methionine load, blood samples will be obtained at 0.5, 1, 1.5, 3, 4.5, 6, 7.5 and 9 hours. Plasma will be analyzed for methionine.</description>
          <units>hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.29" spread="1.86"/>
                    <measurement group_id="O2" value="4.66" spread="1.57"/>
                    <measurement group_id="O3" value="4.25" spread="1.64"/>
                    <measurement group_id="O4" value="4.26" spread="1.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fasting Methionine Concentration of Average Methionine Concentration Versus Time Curve.</title>
        <description>After the methionine load, blood samples will be obtained at 0.5, 1, 1.5, 3, 4.5, 6, 7.5 and 9 hours. Plasma will be analyzed for methionine.</description>
        <time_frame>0.5, 1, 1.5, 3, 4.5, 6, 7.5 and 9 hours*at Week 7*</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1000 mg SAMe (S-adenosyl-L-methionine)</title>
            <description>SAMe 1000 mg: 1000 mg dose group: one 500 mg capsule fasting in the morning and one 500 mg capsule before dinner</description>
          </group>
          <group group_id="O2">
            <title>1500 mg SAMe</title>
            <description>SAMe 1500 mg: 1500 mg dose group: two 500 mg capsules fasting in the morning and one 500 mg capsule before dinner</description>
          </group>
          <group group_id="O3">
            <title>2000 mg SAMe</title>
            <description>SAMe 2000 mg: 2000 mg dose group: two 500 mg capsules fasting in the morning and two 500 mg capsules before dinner</description>
          </group>
          <group group_id="O4">
            <title>No Treatment</title>
            <description>No study drug was administered</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Methionine Concentration of Average Methionine Concentration Versus Time Curve.</title>
          <description>After the methionine load, blood samples will be obtained at 0.5, 1, 1.5, 3, 4.5, 6, 7.5 and 9 hours. Plasma will be analyzed for methionine.</description>
          <units>mcg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.02" spread="0.92"/>
                    <measurement group_id="O2" value="3.81" spread="0.67"/>
                    <measurement group_id="O3" value="5.68" spread="10.13"/>
                    <measurement group_id="O4" value="5.62" spread="8.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>13 Carbon (Natural, Stable Isotope of Carbon) Methionine Breath Test</title>
        <description>parameters cumulative percentage dose of 13 carbon recovered after 30, 60, 90 minutes (cPDR30, cPDR60, cPDR 90) will be evaluated</description>
        <time_frame>0.5, 1, 1.5, 3, 4.5, 6, 7.5 and 9 hours*at Week 7*</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1000 mg SAMe (S-adenosyl-L-methionine)</title>
            <description>SAMe 1000 mg: 1000 mg dose group: one 500 mg capsule fasting in the morning and one 500 mg capsule before dinner</description>
          </group>
          <group group_id="O2">
            <title>1500 mg SAMe</title>
            <description>SAMe 1500 mg: 1500 mg dose group: two 500 mg capsules fasting in the morning and one 500 mg capsule before dinner</description>
          </group>
          <group group_id="O3">
            <title>2000 mg SAMe</title>
            <description>SAMe 2000 mg: 2000 mg dose group: two 500 mg capsules fasting in the morning and two 500 mg capsules before dinner</description>
          </group>
          <group group_id="O4">
            <title>No Treatment</title>
            <description>No study drug was administered</description>
          </group>
        </group_list>
        <measure>
          <title>13 Carbon (Natural, Stable Isotope of Carbon) Methionine Breath Test</title>
          <description>parameters cumulative percentage dose of 13 carbon recovered after 30, 60, 90 minutes (cPDR30, cPDR60, cPDR 90) will be evaluated</description>
          <units>percentage of recovery</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>13C methionine breath test recovery at 30 min (%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.93" spread="0.73"/>
                    <measurement group_id="O2" value="0.77" spread="0.51"/>
                    <measurement group_id="O3" value="0.88" spread="0.66"/>
                    <measurement group_id="O4" value="0.69" spread="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>13C methionine breath test recovery at 60 min (%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.66" spread="1.99"/>
                    <measurement group_id="O2" value="3.49" spread="1.74"/>
                    <measurement group_id="O3" value="3.61" spread="1.78"/>
                    <measurement group_id="O4" value="2.98" spread="1.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>13C methionine breath test recovery at 90 min (%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.69" spread="2.75"/>
                    <measurement group_id="O2" value="6.60" spread="2.56"/>
                    <measurement group_id="O3" value="6.68" spread="2.48"/>
                    <measurement group_id="O4" value="5.74" spread="2.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hepatic Panel (Liver Laboratory Parameters)</title>
        <description>Serum Total Bilirubin (STB), Serum Conjugated Bilirubin (SCB), liver-alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), Gamma Glutamyl Transpeptidase (GGT)</description>
        <time_frame>change from baseline at 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1000 mg SAMe (S-adenosyl-L-methionine)</title>
            <description>SAMe 1000 mg: 1000 mg dose group: one 500 mg capsule fasting in the morning and one 500 mg capsule before dinner</description>
          </group>
          <group group_id="O2">
            <title>1500 mg SAMe</title>
            <description>SAMe 1500 mg: 1500 mg dose group: two 500 mg capsules fasting in the morning and one 500 mg capsule before dinner</description>
          </group>
          <group group_id="O3">
            <title>2000 mg SAMe</title>
            <description>SAMe 2000 mg: 2000 mg dose group: two 500 mg capsules fasting in the morning and two 500 mg capsules before dinner</description>
          </group>
          <group group_id="O4">
            <title>No Treatment</title>
            <description>No study drug was administered</description>
          </group>
        </group_list>
        <measure>
          <title>Hepatic Panel (Liver Laboratory Parameters)</title>
          <description>Serum Total Bilirubin (STB), Serum Conjugated Bilirubin (SCB), liver-alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), Gamma Glutamyl Transpeptidase (GGT)</description>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="7.9"/>
                    <measurement group_id="O2" value="-0.1" spread="13.7"/>
                    <measurement group_id="O3" value="3.4" spread="24.1"/>
                    <measurement group_id="O4" value="-6.0" spread="16.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.2" spread="19.5"/>
                    <measurement group_id="O2" value="-6.3" spread="23.5"/>
                    <measurement group_id="O3" value="-4.9" spread="32.2"/>
                    <measurement group_id="O4" value="-11.9" spread="33.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.1" spread="15.7"/>
                    <measurement group_id="O2" value="-3.0" spread="16.5"/>
                    <measurement group_id="O3" value="-1.2" spread="10.7"/>
                    <measurement group_id="O4" value="-11.6" spread="27.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="33.7"/>
                    <measurement group_id="O2" value="-10.6" spread="62.7"/>
                    <measurement group_id="O3" value="-2.7" spread="35.7"/>
                    <measurement group_id="O4" value="-12.3" spread="48.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Metabolic Panel (Metabolic Laboratory Parameters)</title>
        <description>Fasting lipid profile (cholesterol, HDL (High Density Lipoprotein), LDL (Low Density Lipoprotein)), amino acid profile, homeostasis model assessment (HOMA-R) and fasting glucose.</description>
        <time_frame>change from baseline at 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1000 mg SAMe (S-adenosyl-L-methionine)</title>
            <description>SAMe 1000 mg: 1000 mg dose group: one 500 mg capsule fasting in the morning and one 500 mg capsule before dinner</description>
          </group>
          <group group_id="O2">
            <title>1500 mg SAMe</title>
            <description>SAMe 1500 mg: 1500 mg dose group: two 500 mg capsules fasting in the morning and one 500 mg capsule before dinner</description>
          </group>
          <group group_id="O3">
            <title>2000 mg SAMe</title>
            <description>SAMe 2000 mg: 2000 mg dose group: two 500 mg capsules fasting in the morning and two 500 mg capsules before dinner</description>
          </group>
          <group group_id="O4">
            <title>No Treatment</title>
            <description>No study drug was administered</description>
          </group>
        </group_list>
        <measure>
          <title>Metabolic Panel (Metabolic Laboratory Parameters)</title>
          <description>Fasting lipid profile (cholesterol, HDL (High Density Lipoprotein), LDL (Low Density Lipoprotein)), amino acid profile, homeostasis model assessment (HOMA-R) and fasting glucose.</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.131" spread="0.593"/>
                    <measurement group_id="O2" value="0.046" spread="0.921"/>
                    <measurement group_id="O3" value="-0.265" spread="0.601"/>
                    <measurement group_id="O4" value="-0.134" spread="0.659"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.094" spread="0.166"/>
                    <measurement group_id="O2" value="-0.046" spread="0.254"/>
                    <measurement group_id="O3" value="-0.098" spread="0.169"/>
                    <measurement group_id="O4" value="-0.075" spread="0.188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.125" spread="0.452"/>
                    <measurement group_id="O2" value="0.182" spread="0.762"/>
                    <measurement group_id="O3" value="-0.202" spread="0.589"/>
                    <measurement group_id="O4" value="-0.112" spread="0.558"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HOMA-R</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.837" spread="13.232"/>
                    <measurement group_id="O2" value="0.127" spread="3.763"/>
                    <measurement group_id="O3" value="-1.549" spread="13.321"/>
                    <measurement group_id="O4" value="3.432" spread="10.837"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.068" spread="0.968"/>
                    <measurement group_id="O2" value="0.490" spread="1.486"/>
                    <measurement group_id="O3" value="-0.163" spread="1.009"/>
                    <measurement group_id="O4" value="-0.121" spread="1.610"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Immunological/Anti-oxidant Panel (Immunological and Anti-oxidant Laboratory Parameters)</title>
        <description>Cytokine profile ( Interleukin-6, IL-8, IL-10 (IL), Tumor Necrosis Factor (TNF -α), monocyte chemoattractant protein (MCP-1), and Granulocyte-colony stimulating factor (G-CSF ).</description>
        <time_frame>change from baseline at 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1000 mg SAMe (S-adenosyl-L-methionine)</title>
            <description>SAMe 1000 mg: 1000 mg dose group: one 500 mg capsule fasting in the morning and one 500 mg capsule before dinner</description>
          </group>
          <group group_id="O2">
            <title>1500 mg SAMe</title>
            <description>SAMe 1500 mg: 1500 mg dose group: two 500 mg capsules fasting in the morning and one 500 mg capsule before dinner</description>
          </group>
          <group group_id="O3">
            <title>2000 mg SAMe</title>
            <description>SAMe 2000 mg: 2000 mg dose group: two 500 mg capsules fasting in the morning and two 500 mg capsules before dinner</description>
          </group>
          <group group_id="O4">
            <title>No Treatment</title>
            <description>No study drug was administered</description>
          </group>
        </group_list>
        <measure>
          <title>Immunological/Anti-oxidant Panel (Immunological and Anti-oxidant Laboratory Parameters)</title>
          <description>Cytokine profile ( Interleukin-6, IL-8, IL-10 (IL), Tumor Necrosis Factor (TNF -α), monocyte chemoattractant protein (MCP-1), and Granulocyte-colony stimulating factor (G-CSF ).</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IL-6: n= (27,24,23,27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0603" spread="2.0263"/>
                    <measurement group_id="O2" value="-0.9254" spread="6.4599"/>
                    <measurement group_id="O3" value="-1.3194" spread="4.5779"/>
                    <measurement group_id="O4" value="0.1597" spread="1.6243"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-8: n= (8,6,7,9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.41" spread="41.07"/>
                    <measurement group_id="O2" value="0.65" spread="13.37"/>
                    <measurement group_id="O3" value="-78.73" spread="187.51"/>
                    <measurement group_id="O4" value="-6.17" spread="16.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-10: n= (1,2,1,2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.270">not calculated as there was data of only 1 patient available</measurement>
                    <measurement group_id="O2" value="-0.045" spread="0.106"/>
                    <measurement group_id="O3" value="-0.300">not calculated as there was data of only 1 patient available</measurement>
                    <measurement group_id="O4" value="1.600" spread="1.146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNF-alpha: n= (24,24,20,27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.127" spread="0.414"/>
                    <measurement group_id="O2" value="-1.083" spread="4.782"/>
                    <measurement group_id="O3" value="-0.601" spread="2.136"/>
                    <measurement group_id="O4" value="-0.187" spread="1.114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCP-1: n= (27,25,24,27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.75" spread="154.75"/>
                    <measurement group_id="O2" value="-20.60" spread="79.71"/>
                    <measurement group_id="O3" value="-40.15" spread="96.21"/>
                    <measurement group_id="O4" value="-44.51" spread="114.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G-CSF: n= (5,4,1,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.0" spread="52.8"/>
                    <measurement group_id="O2" value="-0.5" spread="9.7"/>
                    <measurement group_id="O3" value="20.0">not calculated as there was data of only 1 patient available</measurement>
                    <measurement group_id="O4" value="NA">not calculated as there was no data of patients available</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Fibrosis and Apoptosis Markers (Fibrosis and Apoptosis Laboratory Markers)</title>
        <description>Non-invasive test for liver disease (ActiTest)/Fibrotest
FibroTest® : diagnoses hepatic fibrosis ActiTest® : assesses viral necro-inflammatory activity Scores between 0 and 1, the higher the score the worse
The FibroTest score is calculated from the results of a six-parameter blood test, combining six serum markers with the age and gender of the patient:Alpha-2-macroglobulin, Haptoglobin, Apolipoprotein A1, Gamma-glutamyl transpeptidase (GGT), Total bilirubin, and Alanine transaminase (ALT). ALT is used in a second assessment called ActiTest that is part of FibroTest.</description>
        <time_frame>change from baseline at 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1000 mg SAMe (S-adenosyl-L-methionine)</title>
            <description>SAMe 1000 mg: 1000 mg dose group: one 500 mg capsule fasting in the morning and one 500 mg capsule before dinner</description>
          </group>
          <group group_id="O2">
            <title>1500 mg SAMe</title>
            <description>SAMe 1500 mg: 1500 mg dose group: two 500 mg capsules fasting in the morning and one 500 mg capsule before dinner</description>
          </group>
          <group group_id="O3">
            <title>2000 mg SAMe</title>
            <description>SAMe 2000 mg: 2000 mg dose group: two 500 mg capsules fasting in the morning and two 500 mg capsules before dinner</description>
          </group>
          <group group_id="O4">
            <title>No Treatment</title>
            <description>No study drug was administered</description>
          </group>
        </group_list>
        <measure>
          <title>Fibrosis and Apoptosis Markers (Fibrosis and Apoptosis Laboratory Markers)</title>
          <description>Non-invasive test for liver disease (ActiTest)/Fibrotest
FibroTest® : diagnoses hepatic fibrosis ActiTest® : assesses viral necro-inflammatory activity Scores between 0 and 1, the higher the score the worse
The FibroTest score is calculated from the results of a six-parameter blood test, combining six serum markers with the age and gender of the patient:Alpha-2-macroglobulin, Haptoglobin, Apolipoprotein A1, Gamma-glutamyl transpeptidase (GGT), Total bilirubin, and Alanine transaminase (ALT). ALT is used in a second assessment called ActiTest that is part of FibroTest.</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ActiTest Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.017" spread="0.098"/>
                    <measurement group_id="O2" value="-0.022" spread="0.137"/>
                    <measurement group_id="O3" value="-0.002" spread="0.168"/>
                    <measurement group_id="O4" value="-0.042" spread="0.096"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fibrotest Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.036" spread="0.097"/>
                    <measurement group_id="O2" value="0.028" spread="0.093"/>
                    <measurement group_id="O3" value="0.050" spread="0.125"/>
                    <measurement group_id="O4" value="0.020" spread="0.068"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Metabolic Clearance Rate Measured in the Blood.</title>
        <description>After the methionine load, blood samples will be obtained at 0.5, 1, 1.5, 3, 4.5, 6, 7.5 and 9 hours. Plasma will be analyzed for methionine.</description>
        <time_frame>0.5, 1, 1.5, 3, 4.5, 6, 7.5 and 9 hours*at Week 7*</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1000 mg SAMe (S-adenosyl-L-methionine)</title>
            <description>SAMe 1000 mg: 1000 mg dose group: one 500 mg capsule fasting in the morning and one 500 mg capsule before dinner</description>
          </group>
          <group group_id="O2">
            <title>1500 mg SAMe</title>
            <description>SAMe 1500 mg: 1500 mg dose group: two 500 mg capsules fasting in the morning and one 500 mg capsule before dinner</description>
          </group>
          <group group_id="O3">
            <title>2000 mg SAMe</title>
            <description>SAMe 2000 mg: 2000 mg dose group: two 500 mg capsules fasting in the morning and two 500 mg capsules before dinner</description>
          </group>
          <group group_id="O4">
            <title>No Treatment</title>
          </group>
        </group_list>
        <measure>
          <title>The Metabolic Clearance Rate Measured in the Blood.</title>
          <description>After the methionine load, blood samples will be obtained at 0.5, 1, 1.5, 3, 4.5, 6, 7.5 and 9 hours. Plasma will be analyzed for methionine.</description>
          <units>L/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.86" spread="2.93"/>
                    <measurement group_id="O2" value="9.83" spread="3.27"/>
                    <measurement group_id="O3" value="10.05" spread="4.32"/>
                    <measurement group_id="O4" value="8.23" spread="2.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Methionine Volume of Distribution at Week 7 (L)</title>
        <description>After the methionine load, blood samples will be obtained at 0.5, 1, 1.5, 3, 4, 5, 6, 7.5 and 9 hours. Plasma will be analyzed for methionine.</description>
        <time_frame>0.5, 1, 1.5, 3, 4.5, 6, 7.5 and 9 hours*at Week 7*</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1000 mg SAMe (S-adenosyl-L-methionine)</title>
            <description>SAMe 1000 mg: 1000 mg dose group: one 500 mg capsule fasting in the morning and one 500 mg capsule before dinner</description>
          </group>
          <group group_id="O2">
            <title>1500 mg SAMe</title>
            <description>SAMe 1500 mg: 1500 mg dose group: two 500 mg capsules fasting in the morning and one 500 mg capsule before dinner</description>
          </group>
          <group group_id="O3">
            <title>2000 mg SAMe</title>
            <description>SAMe 2000 mg: 2000 mg dose group: two 500 mg capsules fasting in the morning and two 500 mg capsules before dinner</description>
          </group>
          <group group_id="O4">
            <title>No Treatment</title>
            <description>No study drug was administered</description>
          </group>
        </group_list>
        <measure>
          <title>Methionine Volume of Distribution at Week 7 (L)</title>
          <description>After the methionine load, blood samples will be obtained at 0.5, 1, 1.5, 3, 4, 5, 6, 7.5 and 9 hours. Plasma will be analyzed for methionine.</description>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.40" spread="18.43"/>
                    <measurement group_id="O2" value="62.84" spread="14.04"/>
                    <measurement group_id="O3" value="64.58" spread="17.77"/>
                    <measurement group_id="O4" value="8.23" spread="53.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>13 Carbon (Natural, Stable Isotope of Carbon) Methionine Breath Test</title>
        <description>Peak</description>
        <time_frame>0.5, 1, 1.5, 3, 4.5, 6, 7.5 and 9 hours*at Week 7*</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1000 mg SAMe (S-adenosyl-L-methionine)</title>
            <description>SAMe 1000 mg: 1000 mg dose group: one 500 mg capsule fasting in the morning and one 500 mg capsule before dinner</description>
          </group>
          <group group_id="O2">
            <title>1500 mg SAMe</title>
            <description>SAMe 1500 mg: 1500 mg dose group: two 500 mg capsules fasting in the morning and one 500 mg capsule before dinner</description>
          </group>
          <group group_id="O3">
            <title>2000 mg SAMe</title>
            <description>SAMe 2000 mg: 2000 mg dose group: two 500 mg capsules fasting in the morning and two 500 mg capsules before dinner</description>
          </group>
          <group group_id="O4">
            <title>No Treatment</title>
            <description>No study drug was administered</description>
          </group>
        </group_list>
        <measure>
          <title>13 Carbon (Natural, Stable Isotope of Carbon) Methionine Breath Test</title>
          <description>Peak</description>
          <units>Atom %C13</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0972" spread="0.0062"/>
                    <measurement group_id="O2" value="1.0964" spread="0.0052"/>
                    <measurement group_id="O3" value="1.0964" spread="0.0053"/>
                    <measurement group_id="O4" value="1.0949" spread="0.0045"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>13 Carbon (Natural, Stable Isotope of Carbon) Methionine Breath Test</title>
        <description>Time to peak</description>
        <time_frame>0.5, 1, 1.5, 3, 4.5, 6, 7.5 and 9 hours*at Week 7*</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1000 mg SAMe (S-adenosyl-L-methionine)</title>
            <description>SAMe 1000 mg: 1000 mg dose group: one 500 mg capsule fasting in the morning and one 500 mg capsule before dinner</description>
          </group>
          <group group_id="O2">
            <title>1500 mg SAMe</title>
            <description>SAMe 1500 mg: 1500 mg dose group: two 500 mg capsules fasting in the morning and one 500 mg capsule before dinner</description>
          </group>
          <group group_id="O3">
            <title>2000 mg SAMe</title>
            <description>SAMe 2000 mg: 2000 mg dose group: two 500 mg capsules fasting in the morning and two 500 mg capsules before dinner</description>
          </group>
          <group group_id="O4">
            <title>No Treatment</title>
            <description>No study drug was administered</description>
          </group>
        </group_list>
        <measure>
          <title>13 Carbon (Natural, Stable Isotope of Carbon) Methionine Breath Test</title>
          <description>Time to peak</description>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.0" lower_limit="50.0" upper_limit="80.0"/>
                    <measurement group_id="O2" value="70.0" lower_limit="60.0" upper_limit="90.0"/>
                    <measurement group_id="O3" value="70.0" lower_limit="50.0" upper_limit="80.0"/>
                    <measurement group_id="O4" value="70.0" lower_limit="60.0" upper_limit="90.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Metabolic Panel (Metabolic Laboratory Parameters)</title>
        <description>Fasting plasma insulin</description>
        <time_frame>Change from baseline at 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1000 mg SAMe (S-adenosyl-L-methionine)</title>
            <description>SAMe 1000 mg: 1000 mg dose group: one 500 mg capsule fasting in the morning and one 500 mg capsule before dinner</description>
          </group>
          <group group_id="O2">
            <title>1500 mg SAMe</title>
            <description>SAMe 1500 mg: 1500 mg dose group: two 500 mg capsules fasting in the morning and one 500 mg capsule before dinner</description>
          </group>
          <group group_id="O3">
            <title>2000 mg SAMe</title>
            <description>SAMe 2000 mg: 2000 mg dose group: two 500 mg capsules fasting in the morning and two 500 mg capsules before dinner</description>
          </group>
          <group group_id="O4">
            <title>No Treatment</title>
            <description>No study drug was administered</description>
          </group>
        </group_list>
        <measure>
          <title>Metabolic Panel (Metabolic Laboratory Parameters)</title>
          <description>Fasting plasma insulin</description>
          <units>pmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="191.0"/>
                    <measurement group_id="O2" value="-13.6" spread="115.5"/>
                    <measurement group_id="O3" value="-13.1" spread="248"/>
                    <measurement group_id="O4" value="69.1" spread="309.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Metabolic Panel (Metabolic Laboratory Parameters)</title>
        <description>glycosylated hemoglobin (HbA1c)</description>
        <time_frame>change from baseline at 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1000 mg SAMe (S-adenosyl-L-methionine)</title>
            <description>SAMe 1000 mg: 1000 mg dose group: one 500 mg capsule fasting in the morning and one 500 mg capsule before dinner</description>
          </group>
          <group group_id="O2">
            <title>1500 mg SAMe</title>
            <description>SAMe 1500 mg: 1500 mg dose group: two 500 mg capsules fasting in the morning and one 500 mg capsule before dinner</description>
          </group>
          <group group_id="O3">
            <title>2000 mg SAMe</title>
            <description>SAMe 2000 mg: 2000 mg dose group: two 500 mg capsules fasting in the morning and two 500 mg capsules before dinner</description>
          </group>
          <group group_id="O4">
            <title>No Treatment</title>
            <description>No study drug was administered</description>
          </group>
        </group_list>
        <measure>
          <title>Metabolic Panel (Metabolic Laboratory Parameters)</title>
          <description>glycosylated hemoglobin (HbA1c)</description>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.08" spread="0.28"/>
                    <measurement group_id="O2" value="-0.06" spread="0.36"/>
                    <measurement group_id="O3" value="-0.05" spread="0.32"/>
                    <measurement group_id="O4" value="0.02" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Metabolic Panel (Metabolic Laboratory Parameters)</title>
        <description>Adiponectin</description>
        <time_frame>change from baseline at 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1000 mg SAMe (S-adenosyl-L-methionine)</title>
            <description>SAMe 1000 mg: 1000 mg dose group: one 500 mg capsule fasting in the morning and one 500 mg capsule before dinner</description>
          </group>
          <group group_id="O2">
            <title>1500 mg SAMe</title>
            <description>SAMe 1500 mg: 1500 mg dose group: two 500 mg capsules fasting in the morning and one 500 mg capsule before dinner</description>
          </group>
          <group group_id="O3">
            <title>2000 mg SAMe</title>
            <description>SAMe 2000 mg: 2000 mg dose group: two 500 mg capsules fasting in the morning and two 500 mg capsules before dinner</description>
          </group>
          <group group_id="O4">
            <title>No Treatment</title>
            <description>No study drug was administered</description>
          </group>
        </group_list>
        <measure>
          <title>Metabolic Panel (Metabolic Laboratory Parameters)</title>
          <description>Adiponectin</description>
          <units>mcg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.754" spread="4.191"/>
                    <measurement group_id="O2" value="0.425" spread="1.199"/>
                    <measurement group_id="O3" value="0.219" spread="1.661"/>
                    <measurement group_id="O4" value="0.045" spread="1.515"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunological/Anti-oxidant Panel (Immunological and Anti-oxidant Laboratory Parameters)</title>
        <description>C-reactive Protein (CRP)</description>
        <time_frame>change from baseline at 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1000 mg SAMe (S-adenosyl-L-methionine)</title>
            <description>SAMe 1000 mg: 1000 mg dose group: one 500 mg capsule fasting in the morning and one 500 mg capsule before dinner</description>
          </group>
          <group group_id="O2">
            <title>1500 mg SAMe</title>
            <description>SAMe 1500 mg: 1500 mg dose group: two 500 mg capsules fasting in the morning and one 500 mg capsule before dinner</description>
          </group>
          <group group_id="O3">
            <title>2000 mg SAMe</title>
            <description>SAMe 2000 mg: 2000 mg dose group: two 500 mg capsules fasting in the morning and two 500 mg capsules before dinner</description>
          </group>
          <group group_id="O4">
            <title>No Treatment</title>
            <description>No study drug was administered</description>
          </group>
        </group_list>
        <measure>
          <title>Immunological/Anti-oxidant Panel (Immunological and Anti-oxidant Laboratory Parameters)</title>
          <description>C-reactive Protein (CRP)</description>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.79" spread="15.51"/>
                    <measurement group_id="O2" value="-0.80" spread="14.90"/>
                    <measurement group_id="O3" value="-8.02" spread="20.40"/>
                    <measurement group_id="O4" value="-4.80" spread="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunological/Anti-oxidant Panel (Immunological and Anti-oxidant Laboratory Parameters)</title>
        <description>glutathione in erythrocytes</description>
        <time_frame>change from baseline at 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1000 mg SAMe (S-adenosyl-L-methionine)</title>
            <description>SAMe 1000 mg: 1000 mg dose group: one 500 mg capsule fasting in the morning and one 500 mg capsule before dinner</description>
          </group>
          <group group_id="O2">
            <title>1500 mg SAMe</title>
            <description>SAMe 1500 mg: 1500 mg dose group: two 500 mg capsules fasting in the morning and one 500 mg capsule before dinner</description>
          </group>
          <group group_id="O3">
            <title>2000 mg SAMe</title>
            <description>SAMe 2000 mg: 2000 mg dose group: two 500 mg capsules fasting in the morning and two 500 mg capsules before dinner</description>
          </group>
          <group group_id="O4">
            <title>No Treatment</title>
            <description>No study drug was administered</description>
          </group>
        </group_list>
        <measure>
          <title>Immunological/Anti-oxidant Panel (Immunological and Anti-oxidant Laboratory Parameters)</title>
          <description>glutathione in erythrocytes</description>
          <units>mcmol/g</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.24" spread="2.06"/>
                    <measurement group_id="O2" value="-0.21" spread="1.01"/>
                    <measurement group_id="O3" value="0.05" spread="1.41"/>
                    <measurement group_id="O4" value="-0.30" spread="1.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunological/Anti-oxidant Panel (Immunological and Anti-oxidant Laboratory Parameters)</title>
        <description>oxidative stress marker (isoprostane level)</description>
        <time_frame>change from baseline at 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1000 mg SAMe (S-adenosyl-L-methionine)</title>
            <description>SAMe 1000 mg: 1000 mg dose group: one 500 mg capsule fasting in the morning and one 500 mg capsule before dinner</description>
          </group>
          <group group_id="O2">
            <title>1500 mg SAMe</title>
            <description>SAMe 1500 mg: 1500 mg dose group: two 500 mg capsules fasting in the morning and one 500 mg capsule before dinner</description>
          </group>
          <group group_id="O3">
            <title>2000 mg SAMe</title>
            <description>SAMe 2000 mg: 2000 mg dose group: two 500 mg capsules fasting in the morning and two 500 mg capsules before dinner</description>
          </group>
          <group group_id="O4">
            <title>No Treatment</title>
            <description>No study drug was administered</description>
          </group>
        </group_list>
        <measure>
          <title>Immunological/Anti-oxidant Panel (Immunological and Anti-oxidant Laboratory Parameters)</title>
          <description>oxidative stress marker (isoprostane level)</description>
          <units>ng/mg Crea</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.223" spread="0.801"/>
                    <measurement group_id="O2" value="0.116" spread="0.699"/>
                    <measurement group_id="O3" value="0.290" spread="0.691"/>
                    <measurement group_id="O4" value="-0.223" spread="0.641"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fibrosis and Apoptosis Markers (Fibrosis and Apoptosis Laboratory Markers)</title>
        <description>Caspase-cleaved cytokeratin (CK 18)</description>
        <time_frame>change from baseline at 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1000 mg SAMe (S-adenosyl-L-methionine)</title>
            <description>SAMe 1000 mg: 1000 mg dose group: one 500 mg capsule fasting in the morning and one 500 mg capsule before dinner</description>
          </group>
          <group group_id="O2">
            <title>1500 mg SAMe</title>
            <description>SAMe 1500 mg: 1500 mg dose group: two 500 mg capsules fasting in the morning and one 500 mg capsule before dinner</description>
          </group>
          <group group_id="O3">
            <title>2000 mg SAMe</title>
            <description>SAMe 2000 mg: 2000 mg dose group: two 500 mg capsules fasting in the morning and two 500 mg capsules before dinner</description>
          </group>
          <group group_id="O4">
            <title>No Treatment</title>
            <description>No study drug was administered</description>
          </group>
        </group_list>
        <measure>
          <title>Fibrosis and Apoptosis Markers (Fibrosis and Apoptosis Laboratory Markers)</title>
          <description>Caspase-cleaved cytokeratin (CK 18)</description>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-126.8" spread="401.1"/>
                    <measurement group_id="O2" value="-136.6" spread="257.3"/>
                    <measurement group_id="O3" value="-47.0" spread="157.3"/>
                    <measurement group_id="O4" value="-143.2" spread="532.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fibrosis and Apoptosis Markers (Fibrosis and Apoptosis Laboratory Markers)</title>
        <description>Hyaluronic acid</description>
        <time_frame>change from baseline at 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1000 mg SAMe (S-adenosyl-L-methionine)</title>
            <description>SAMe 1000 mg: 1000 mg dose group: one 500 mg capsule fasting in the morning and one 500 mg capsule before dinner</description>
          </group>
          <group group_id="O2">
            <title>1500 mg SAMe</title>
            <description>SAMe 1500 mg: 1500 mg dose group: two 500 mg capsules fasting in the morning and one 500 mg capsule before dinner</description>
          </group>
          <group group_id="O3">
            <title>2000 mg SAMe</title>
            <description>SAMe 2000 mg: 2000 mg dose group: two 500 mg capsules fasting in the morning and two 500 mg capsules before dinner</description>
          </group>
          <group group_id="O4">
            <title>No Treatment</title>
            <description>No study drug was administered</description>
          </group>
        </group_list>
        <measure>
          <title>Fibrosis and Apoptosis Markers (Fibrosis and Apoptosis Laboratory Markers)</title>
          <description>Hyaluronic acid</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.67" spread="48.52"/>
                    <measurement group_id="O2" value="2.03" spread="32.26"/>
                    <measurement group_id="O3" value="9.40" spread="59.63"/>
                    <measurement group_id="O4" value="3.02" spread="46.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under Curve (AUC) of Average Methionine Concentration Versus Time Curve</title>
        <description>After the methionine load, blood samples will be obtained at 0.5, 1, 1.5, 3, 4, 5, 6, 7.5 and 9 hours. Plasma will be analyzed for methionine.</description>
        <time_frame>0.5, 1, 1.5, 3, 4, 5, 6, 7.5 and 9 hours *at Week 7*</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1000 mg SAMe (S-adenosyl-L-methionine)</title>
            <description>SAMe 1000 mg: 1000 mg dose group: one 500 mg capsule fasting in the morning and one 500 mg capsule before dinner</description>
          </group>
          <group group_id="O2">
            <title>1500 mg SAMe</title>
            <description>SAMe 1500 mg: 1500 mg dose group: two 500 mg capsules fasting in the morning and one 500 mg capsule before dinner</description>
          </group>
          <group group_id="O3">
            <title>2000 mg SAMe</title>
            <description>SAMe 2000 mg: 2000 mg dose group: two 500 mg capsules fasting in the morning and two 500 mg capsules before dinner</description>
          </group>
          <group group_id="O4">
            <title>No Treatment</title>
            <description>No study drug was administered</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under Curve (AUC) of Average Methionine Concentration Versus Time Curve</title>
          <description>After the methionine load, blood samples will be obtained at 0.5, 1, 1.5, 3, 4, 5, 6, 7.5 and 9 hours. Plasma will be analyzed for methionine.</description>
          <units>mcg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="440.09" spread="149.96"/>
                    <measurement group_id="O2" value="399.30" spread="148.90"/>
                    <measurement group_id="O3" value="425.24" spread="231.88"/>
                    <measurement group_id="O4" value="460.57" spread="135.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hepatic Panel (Liver Laboratory Parameters)</title>
        <description>ALT/AST ratio</description>
        <time_frame>change from baseline at 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1000 mg SAMe (S-adenosyl-L-methionine)</title>
            <description>SAMe 1000 mg: 1000 mg dose group: one 500 mg capsule fasting in the morning and one 500 mg capsule before dinner</description>
          </group>
          <group group_id="O2">
            <title>1500 mg SAMe</title>
            <description>SAMe 1500 mg: 1500 mg dose group: two 500 mg capsules fasting in the morning and one 500 mg capsule before dinner</description>
          </group>
          <group group_id="O3">
            <title>2000 mg SAMe</title>
            <description>SAMe 2000 mg: 2000 mg dose group: two 500 mg capsules fasting in the morning and two 500 mg capsules before dinner</description>
          </group>
          <group group_id="O4">
            <title>No Treatment</title>
            <description>No study drug was administered</description>
          </group>
        </group_list>
        <measure>
          <title>Hepatic Panel (Liver Laboratory Parameters)</title>
          <description>ALT/AST ratio</description>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" spread="0.23"/>
                    <measurement group_id="O2" value="0.01" spread="0.21"/>
                    <measurement group_id="O3" value="0.03" spread="0.18"/>
                    <measurement group_id="O4" value="-0.01" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>1000 mg SAMe (S-adenosyl-L-methionine)</title>
          <description>SAMe 1000 mg: 1000 mg dose group: one 500 mg capsule fasting in the morning and one 500 mg capsule before dinner</description>
        </group>
        <group group_id="E2">
          <title>1500 mg SAMe</title>
          <description>SAMe 1500 mg: 1500 mg dose group: two 500 mg capsules fasting in the morning and one 500 mg capsule before dinner</description>
        </group>
        <group group_id="E3">
          <title>2000 mg SAMe</title>
          <description>SAMe 2000 mg: 2000 mg dose group: two 500 mg capsules fasting in the morning and two 500 mg capsules before dinner</description>
        </group>
        <group group_id="E4">
          <title>No Treatment</title>
          <description>No study drug was administered</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>head injury and neck injury before start of treatment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Associate Director Clinical Services</name_or_title>
      <organization>Abbott</organization>
      <phone>+31 29-44-79-196</phone>
      <email>taco.baardman@abbott.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

